<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Effect of intensive versus standard blood glucose control on major microvascular outcomes in type 2 diabetes</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Effect of intensive versus standard blood glucose control on major microvascular outcomes in type 2 diabetes</h1>
<div class="graphic"><div class="figure"><div class="ttl">Effect of intensive versus standard blood glucose control on major microvascular outcomes in type 2 diabetes</div><div class="cntnt"><table cellspacing="0"><colgroup span="7" width="14%"></colgroup> <tbody> <tr> <td class="subtitle1">Study</td> <td class="subtitle1">Kumamoto study</td> <td class="subtitle1">UKPDS 33</td> <td class="subtitle1">UKPDS 80<br/> (post-UKPDS 33)</td> <td class="subtitle1">ACCORD</td> <td class="subtitle1">ADVANCE</td> <td class="subtitle1">VADT</td> </tr> <tr class="divider_bottom"> <td>Population</td> <td class="centered">110</td> <td class="centered">4209</td> <td class="centered">3277</td> <td class="centered">10,251</td> <td class="centered">11,140</td> <td class="centered">1791</td> </tr> <tr class="divider_bottom"> <td>Age<br/> (years)</td> <td class="centered">47-52</td> <td class="centered">53</td> <td class="centered"> </td> <td class="centered">62</td> <td class="centered">66</td> <td class="centered">60</td> </tr> <tr class="divider_bottom"> <td>BMI<br/> (kg/m<sup>2</sup>)</td> <td class="centered">19-21</td> <td class="centered">28</td> <td class="centered"> </td> <td class="centered">32</td> <td class="centered">28</td> <td class="centered">31</td> </tr> <tr class="divider_bottom"> <td>Complications</td> <td class="centered">–/+</td> <td class="centered">–/+</td> <td class="centered"> </td> <td class="centered">++</td> <td class="centered">++</td> <td class="centered">++</td> </tr> <tr class="divider_bottom"> <td>Disease duration<br/> (years)</td> <td class="centered">6-10</td> <td class="centered">0</td> <td class="centered"> </td> <td class="centered">10</td> <td class="centered">8</td> <td class="centered">11.5</td> </tr> <tr class="divider_bottom"> <td>Baseline A1C<br/> (%)</td> <td class="centered">8.9-9.4</td> <td class="centered">7.1</td> <td class="centered"> </td> <td class="centered">8.3</td> <td class="centered">7.5</td> <td class="centered">9.4</td> </tr> <tr class="divider_bottom"> <td>Post-trial A1C<br/> (intensive versus standard; %)</td> <td class="centered">7.1 versus 9.4</td> <td class="centered">7.0 versus 7.9</td> <td class="centered"> </td> <td class="centered">6.3 versus 7.5</td> <td class="centered">6.5 versus 7.3</td> <td class="centered">7.0 versus 8.5</td> </tr> <tr> <td colspan="7">Microvascular endpoints</td> </tr> <tr> <td class="indent1">Retinopathy</td> <td> <p>0.31 (0.13-0.76)</p> ≥2-step cumulative change</td> <td> <p>0.75 (0.60-0.98)</p> Any microvascular outcome</td> <td> <p>0.76 (0.64-0.89)</p> Any microvascular outcome</td> <td> <p>0.67 (0.51-<span style="white-space: nowrap;">0.87)*</span></p> 3-step progression</td> <td> <p>0.72 (0.44-<span style="white-space: nowrap;">1.17)*</span></p> 3-step progression</td> <td> <p>0.77 (0.58-1.02)</p> 2-step progression</td> </tr> <tr> <td class="indent1">Nephropathy</td> <td> <p>0.30 (0.11-0.86)</p> New or worsening nephropathy</td> <td> </td> <td> </td> <td> <p>0.72 (0.61-0.84)</p> Incident macroalbuminuria</td> <td> <p>0.79 (0.66-0.93)</p> New or worsening nephropathy</td> <td> <p>0.65 (0.49-0.89)</p> Any increase in albuminuria</td> </tr> <tr> <td class="indent1">Neuropathy</td> <td> </td> <td> </td> <td> </td> <td> <p>0.92 (0.86-0.99)</p> Neuropathy (MNSI&gt;2)</td> <td> </td> <td> <p>0.99 (0.87-1.14)</p> Any new neuropathy</td> </tr> </tbody></table></div><div class="graphic_footnotes">UKPDS: United Kingdom Prospective Diabetes Study; ACCORD: Action to Control Cardiovascular Risk in Diabetes; ADVANCE: Action in Diabetes and Vascular Disease; VADT: Veterans Affairs Diabetes Trial; BMI: body mass index; A1C: glycated hemoglobin; MNSI: Michigan Neuropathy Screening Instrument.<br/>* Data are relative risk (95% confidence interval) or odds ratio.</div><div class="graphic_reference">Modified from: Pozzilli P, Strollo R, Bonora E. One size does not fit all glycemic targets for type 2 diabetes. J Diabetes Investig 2014; 5(2):134-141. <a href="https://onlinelibrary.wiley.com/doi/10.1111/jdi.12206" target="_blank">https://onlinelibrary.wiley.com/doi/10.1111/jdi.12206</a>. Copyright © 2014 The Authors. Journal of Diabetes Investigation published by Asian Association of the Study of Diabetes (AASD) and Wiley Publishing Asia Pty Ltd. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href="/cdn-cgi/l/email-protection#75051007181c06061c1a1b0635021c19100c5b161a18"><span class="__cf_email__" data-cfemail="29594c5b44405a5a4046475a695e40454c50074a4644">[email protected]</span></a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href="https://onlinelibrary.wiley.com/" target="_blank">https://onlinelibrary.wiley.com/</a>).</div><div id="graphicVersion">Graphic 126680 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
